Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sequella Receives Two-year SBIR Grant From NIH
Sequella has received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID). The
Sequella has received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID). The
QRxPharma has reported a contractual agreement with Patheon to manufacture clinical supplies of its controlled release Dual-Opioid formulation – MoxDuoCR. MoxDuoCR is designed to provide 12 hours of
GlaxoSmithKline (GSK) has reported the final results from its four-year CombAT (Combination therapy with Avodart and Tamsulosin) study. The results show that combined treatment with Avodart and tamsulosin
Ablynx has reached a settlement with Domantis, part of the GlaxoSmithKline group of companies, concerning an alleged dispute relating to a settlement agreement which Ablynx and Domantis entered
Phyton Biotech (PB), an affiliate of Phyton, has purchased the assets of Natural Pharmaceuticals (NPI). Under the terms of the agreement, PB will acquire assets of NPI, which
The European Patent Office intends to grant a European patent to Phyton Biotech (Phyton) for its methods of producing taxanes such as paclitaxel. Paclitaxel, the active ingredient in
PhysioNetics has received a $750,000 phase II grant from National Institutes of Health (NIH) to continue its development work on an new ‘gripper’ for upper-extremity prostheses. The fund
DARA BioSciences (DARA) has entered into an Addendum and First Amendment to Material Transfer Agreement with America Stem Cell (ASC), pursuant to which the Material Transfer Agreement between
Kaiser Permanente Research Program on Genes, Environment and Health (RPGEH) and the University of California, San Francisco (UCSF) have been awarded a grant of $24.8m over two years
BioScience Laboratories and Synomics Pharmaceutical have reported their formal partnership to provide a fully integrated phase 1 clinical study capability for trials in healthy human subjects. The objective